A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C
Background/Aims : In chronic hepatitis C, interferon alfa (IFN-α) therapy fails to achieve a sustained response in approximately 75% of patients. Similarly, ribavirin induces only a transient response. The aim of this study was to evaluate whether ribavirin and IFN-α in combination could be effectiv...
Gespeichert in:
| Veröffentlicht in: | Gastroenterology (New York, N.Y. 1943) N.Y. 1943), 1994-09, Vol.107 (3), p.812-817 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 817 |
|---|---|
| container_issue | 3 |
| container_start_page | 812 |
| container_title | Gastroenterology (New York, N.Y. 1943) |
| container_volume | 107 |
| creator | Brillanti, Stefano Garson, Jeremy Foli, Mauro Whitby, Kevin Deaville, Robert Masci, Caterina Miglioli, Mario Barbara, Luigi |
| description | Background/Aims
:
In chronic hepatitis C, interferon alfa (IFN-α) therapy fails to achieve a sustained response in approximately 75% of patients. Similarly, ribavirin induces only a transient response. The aim of this study was to evaluate whether ribavirin and IFN-α in combination could be effective in IFN-α-resistant chronic hepatitis C.
Methods
:
Twenty patients with chronic hepatitis C resistant to a previous course of IFN-α were randomly assigned to receive either ribavirin combined with IFN-α or IFN-α alone for 6 months.
Results
:
Serum alanine aminotransferase levels decreased significantly during therapy in both treatment groups, but after therapy, the levels remained significantly decreased only in the combination therapy group. Nine months after treatment, sustained normalization of aminotransferase levels, associated with sustained loss of serum hepatitis C virus RNA, was observed in 40% of the patients in the combination therapy group but in none of the patients treated with IFN-α alone (
P < 0.05). The sustained response was accompanied by reduced hepatic necroinflammatory activity on biopsy.
Conclusions
:
These findings suggest that ribavirin plus IFN-α combination therapy is able to induce a sustained biochemical and virological response in a significant proportion of patients with IFN-α-resistant chronic hepatitis C. |
| doi_str_mv | 10.1016/0016-5085(94)90131-7 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_76692226</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>0016508594901317</els_id><sourcerecordid>76692226</sourcerecordid><originalsourceid>FETCH-LOGICAL-c403t-2ba24d707e39389b164950664ae2fb627633428336933ced9e225b504ec8bdf93</originalsourceid><addsrcrecordid>eNp9kE9r3DAQxUVpSLZpv0ELOpX04FT_LFuXQliSJhDIpT0LWR6zU7yWI8kJm08fbXfJoYdeZmDem6fRj5DPnF1yxvV3VkpVs7a-MOqbYVzyqnlHVrwWbVU08Z6s3ixn5ENKfxhjRrb8lJw2teCStSvyckVnHEOmKS_9joaB-rDtcHIZw0TzBqKbd_QZ84ZG7NwTRpzoPC6J4pQhDhCLzY2Do0OI_86qCAlTdlOmflOG6OkG5hKdMdH1R3IyuDHBp2M_J79vrn-tb6v7h59366v7yismcyU6J1TfsAZkOd50XCtTM62VAzF0WjRaSiVaKbWR0kNvQIi6q5kC33b9YOQ5-XrInWN4XCBlu8XkYRzdBGFJttHaCCF0MaqD0ceQUoTBzhG3Lu4sZ3aP3O552j1Pa5T9i9w2Ze3LMX_pttC_LR0ZF_3HQYfyySeEaJNHmMqpGMFn2wf8_wOvytaRZg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>76692226</pqid></control><display><type>article</type><title>A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><source>Alma/SFX Local Collection</source><creator>Brillanti, Stefano ; Garson, Jeremy ; Foli, Mauro ; Whitby, Kevin ; Deaville, Robert ; Masci, Caterina ; Miglioli, Mario ; Barbara, Luigi</creator><creatorcontrib>Brillanti, Stefano ; Garson, Jeremy ; Foli, Mauro ; Whitby, Kevin ; Deaville, Robert ; Masci, Caterina ; Miglioli, Mario ; Barbara, Luigi</creatorcontrib><description>Background/Aims
:
In chronic hepatitis C, interferon alfa (IFN-α) therapy fails to achieve a sustained response in approximately 75% of patients. Similarly, ribavirin induces only a transient response. The aim of this study was to evaluate whether ribavirin and IFN-α in combination could be effective in IFN-α-resistant chronic hepatitis C.
Methods
:
Twenty patients with chronic hepatitis C resistant to a previous course of IFN-α were randomly assigned to receive either ribavirin combined with IFN-α or IFN-α alone for 6 months.
Results
:
Serum alanine aminotransferase levels decreased significantly during therapy in both treatment groups, but after therapy, the levels remained significantly decreased only in the combination therapy group. Nine months after treatment, sustained normalization of aminotransferase levels, associated with sustained loss of serum hepatitis C virus RNA, was observed in 40% of the patients in the combination therapy group but in none of the patients treated with IFN-α alone (
P < 0.05). The sustained response was accompanied by reduced hepatic necroinflammatory activity on biopsy.
Conclusions
:
These findings suggest that ribavirin plus IFN-α combination therapy is able to induce a sustained biochemical and virological response in a significant proportion of patients with IFN-α-resistant chronic hepatitis C.</description><identifier>ISSN: 0016-5085</identifier><identifier>EISSN: 1528-0012</identifier><identifier>DOI: 10.1016/0016-5085(94)90131-7</identifier><identifier>PMID: 7521308</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adult ; Alanine Transaminase - blood ; Chronic Disease ; Drug Resistance, Microbial ; Drug Therapy, Combination ; Female ; Hepacivirus - genetics ; Hepatitis C - drug therapy ; Humans ; Interferon-alpha - adverse effects ; Interferon-alpha - therapeutic use ; Liver - pathology ; Male ; Middle Aged ; Pilot Projects ; Ribavirin - adverse effects ; Ribavirin - therapeutic use ; RNA - blood</subject><ispartof>Gastroenterology (New York, N.Y. 1943), 1994-09, Vol.107 (3), p.812-817</ispartof><rights>1994</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c403t-2ba24d707e39389b164950664ae2fb627633428336933ced9e225b504ec8bdf93</citedby><cites>FETCH-LOGICAL-c403t-2ba24d707e39389b164950664ae2fb627633428336933ced9e225b504ec8bdf93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/0016508594901317$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/7521308$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Brillanti, Stefano</creatorcontrib><creatorcontrib>Garson, Jeremy</creatorcontrib><creatorcontrib>Foli, Mauro</creatorcontrib><creatorcontrib>Whitby, Kevin</creatorcontrib><creatorcontrib>Deaville, Robert</creatorcontrib><creatorcontrib>Masci, Caterina</creatorcontrib><creatorcontrib>Miglioli, Mario</creatorcontrib><creatorcontrib>Barbara, Luigi</creatorcontrib><title>A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C</title><title>Gastroenterology (New York, N.Y. 1943)</title><addtitle>Gastroenterology</addtitle><description>Background/Aims
:
In chronic hepatitis C, interferon alfa (IFN-α) therapy fails to achieve a sustained response in approximately 75% of patients. Similarly, ribavirin induces only a transient response. The aim of this study was to evaluate whether ribavirin and IFN-α in combination could be effective in IFN-α-resistant chronic hepatitis C.
Methods
:
Twenty patients with chronic hepatitis C resistant to a previous course of IFN-α were randomly assigned to receive either ribavirin combined with IFN-α or IFN-α alone for 6 months.
Results
:
Serum alanine aminotransferase levels decreased significantly during therapy in both treatment groups, but after therapy, the levels remained significantly decreased only in the combination therapy group. Nine months after treatment, sustained normalization of aminotransferase levels, associated with sustained loss of serum hepatitis C virus RNA, was observed in 40% of the patients in the combination therapy group but in none of the patients treated with IFN-α alone (
P < 0.05). The sustained response was accompanied by reduced hepatic necroinflammatory activity on biopsy.
Conclusions
:
These findings suggest that ribavirin plus IFN-α combination therapy is able to induce a sustained biochemical and virological response in a significant proportion of patients with IFN-α-resistant chronic hepatitis C.</description><subject>Adult</subject><subject>Alanine Transaminase - blood</subject><subject>Chronic Disease</subject><subject>Drug Resistance, Microbial</subject><subject>Drug Therapy, Combination</subject><subject>Female</subject><subject>Hepacivirus - genetics</subject><subject>Hepatitis C - drug therapy</subject><subject>Humans</subject><subject>Interferon-alpha - adverse effects</subject><subject>Interferon-alpha - therapeutic use</subject><subject>Liver - pathology</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Pilot Projects</subject><subject>Ribavirin - adverse effects</subject><subject>Ribavirin - therapeutic use</subject><subject>RNA - blood</subject><issn>0016-5085</issn><issn>1528-0012</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1994</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE9r3DAQxUVpSLZpv0ELOpX04FT_LFuXQliSJhDIpT0LWR6zU7yWI8kJm08fbXfJoYdeZmDem6fRj5DPnF1yxvV3VkpVs7a-MOqbYVzyqnlHVrwWbVU08Z6s3ixn5ENKfxhjRrb8lJw2teCStSvyckVnHEOmKS_9joaB-rDtcHIZw0TzBqKbd_QZ84ZG7NwTRpzoPC6J4pQhDhCLzY2Do0OI_86qCAlTdlOmflOG6OkG5hKdMdH1R3IyuDHBp2M_J79vrn-tb6v7h59366v7yismcyU6J1TfsAZkOd50XCtTM62VAzF0WjRaSiVaKbWR0kNvQIi6q5kC33b9YOQ5-XrInWN4XCBlu8XkYRzdBGFJttHaCCF0MaqD0ceQUoTBzhG3Lu4sZ3aP3O552j1Pa5T9i9w2Ze3LMX_pttC_LR0ZF_3HQYfyySeEaJNHmMqpGMFn2wf8_wOvytaRZg</recordid><startdate>19940901</startdate><enddate>19940901</enddate><creator>Brillanti, Stefano</creator><creator>Garson, Jeremy</creator><creator>Foli, Mauro</creator><creator>Whitby, Kevin</creator><creator>Deaville, Robert</creator><creator>Masci, Caterina</creator><creator>Miglioli, Mario</creator><creator>Barbara, Luigi</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19940901</creationdate><title>A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C</title><author>Brillanti, Stefano ; Garson, Jeremy ; Foli, Mauro ; Whitby, Kevin ; Deaville, Robert ; Masci, Caterina ; Miglioli, Mario ; Barbara, Luigi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c403t-2ba24d707e39389b164950664ae2fb627633428336933ced9e225b504ec8bdf93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1994</creationdate><topic>Adult</topic><topic>Alanine Transaminase - blood</topic><topic>Chronic Disease</topic><topic>Drug Resistance, Microbial</topic><topic>Drug Therapy, Combination</topic><topic>Female</topic><topic>Hepacivirus - genetics</topic><topic>Hepatitis C - drug therapy</topic><topic>Humans</topic><topic>Interferon-alpha - adverse effects</topic><topic>Interferon-alpha - therapeutic use</topic><topic>Liver - pathology</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Pilot Projects</topic><topic>Ribavirin - adverse effects</topic><topic>Ribavirin - therapeutic use</topic><topic>RNA - blood</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Brillanti, Stefano</creatorcontrib><creatorcontrib>Garson, Jeremy</creatorcontrib><creatorcontrib>Foli, Mauro</creatorcontrib><creatorcontrib>Whitby, Kevin</creatorcontrib><creatorcontrib>Deaville, Robert</creatorcontrib><creatorcontrib>Masci, Caterina</creatorcontrib><creatorcontrib>Miglioli, Mario</creatorcontrib><creatorcontrib>Barbara, Luigi</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Gastroenterology (New York, N.Y. 1943)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Brillanti, Stefano</au><au>Garson, Jeremy</au><au>Foli, Mauro</au><au>Whitby, Kevin</au><au>Deaville, Robert</au><au>Masci, Caterina</au><au>Miglioli, Mario</au><au>Barbara, Luigi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C</atitle><jtitle>Gastroenterology (New York, N.Y. 1943)</jtitle><addtitle>Gastroenterology</addtitle><date>1994-09-01</date><risdate>1994</risdate><volume>107</volume><issue>3</issue><spage>812</spage><epage>817</epage><pages>812-817</pages><issn>0016-5085</issn><eissn>1528-0012</eissn><abstract>Background/Aims
:
In chronic hepatitis C, interferon alfa (IFN-α) therapy fails to achieve a sustained response in approximately 75% of patients. Similarly, ribavirin induces only a transient response. The aim of this study was to evaluate whether ribavirin and IFN-α in combination could be effective in IFN-α-resistant chronic hepatitis C.
Methods
:
Twenty patients with chronic hepatitis C resistant to a previous course of IFN-α were randomly assigned to receive either ribavirin combined with IFN-α or IFN-α alone for 6 months.
Results
:
Serum alanine aminotransferase levels decreased significantly during therapy in both treatment groups, but after therapy, the levels remained significantly decreased only in the combination therapy group. Nine months after treatment, sustained normalization of aminotransferase levels, associated with sustained loss of serum hepatitis C virus RNA, was observed in 40% of the patients in the combination therapy group but in none of the patients treated with IFN-α alone (
P < 0.05). The sustained response was accompanied by reduced hepatic necroinflammatory activity on biopsy.
Conclusions
:
These findings suggest that ribavirin plus IFN-α combination therapy is able to induce a sustained biochemical and virological response in a significant proportion of patients with IFN-α-resistant chronic hepatitis C.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>7521308</pmid><doi>10.1016/0016-5085(94)90131-7</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0016-5085 |
| ispartof | Gastroenterology (New York, N.Y. 1943), 1994-09, Vol.107 (3), p.812-817 |
| issn | 0016-5085 1528-0012 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_76692226 |
| source | MEDLINE; Elsevier ScienceDirect Journals; Alma/SFX Local Collection |
| subjects | Adult Alanine Transaminase - blood Chronic Disease Drug Resistance, Microbial Drug Therapy, Combination Female Hepacivirus - genetics Hepatitis C - drug therapy Humans Interferon-alpha - adverse effects Interferon-alpha - therapeutic use Liver - pathology Male Middle Aged Pilot Projects Ribavirin - adverse effects Ribavirin - therapeutic use RNA - blood |
| title | A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T11%3A25%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20pilot%20study%20of%20combination%20therapy%20with%20ribavirin%20plus%20interferon%20alfa%20for%20interferon%20alfa-resistant%20chronic%20hepatitis%20C&rft.jtitle=Gastroenterology%20(New%20York,%20N.Y.%201943)&rft.au=Brillanti,%20Stefano&rft.date=1994-09-01&rft.volume=107&rft.issue=3&rft.spage=812&rft.epage=817&rft.pages=812-817&rft.issn=0016-5085&rft.eissn=1528-0012&rft_id=info:doi/10.1016/0016-5085(94)90131-7&rft_dat=%3Cproquest_cross%3E76692226%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=76692226&rft_id=info:pmid/7521308&rft_els_id=0016508594901317&rfr_iscdi=true |